Internship

Quality Systems Intern

Confirmed live in the last 24 hours

Arcellx

Arcellx

51-200 employees

Develops immunotherapies for cell therapy

No salary listed

North Bethesda, MD, USA + 1 more

More locations: San Carlos, CA, USA

Category
Public Health
Biology Lab & Research
Biology & Biotech
Required Skills
Word/Pages/Docs
Excel/Numbers/Sheets
Requirements
  • Currently working on a BS in a scientific (or related) discipline with prior work-related experience
  • Strong organizational and prioritization skills, with the ability to meet tight deadlines in a fast-paced environment
  • Excellent written & verbal communication skills
  • Strong experience with MS Excel, Word, PowerPoint and Outlook is required
Responsibilities
  • Participate in implementation and validation of new quality systems modules in Veeva such as station manager and eTMF
  • Assist with document control activities, such as creating/editing/reviewing documents for SOP’s, OJTs
  • Support the improvement initiatives around quality system training and metrics
  • Communicate and promote a culture of quality and operational excellence at Arcellx

Arcellx develops immunotherapies aimed at transforming cell therapy for serious diseases. The company focuses on creating proprietary products that utilize advanced cell therapy techniques. Their approach involves extensive research and development to ensure the safety and effectiveness of their treatments. Arcellx differentiates itself from competitors by concentrating on unmet medical needs and forming partnerships and licensing agreements to support their commercialization efforts. The ultimate goal of Arcellx is to provide innovative treatment options that improve patient outcomes in the healthcare sector.

Company Size

51-200

Company Stage

IPO

Headquarters

Gaithersburg, Maryland

Founded

2014

Simplify Jobs

Simplify's Take

What believers are saying

  • Global CAR-T market projected to grow at 34.5% CAGR until 2030.
  • FDA's support for fast-tracking therapies benefits Arcellx's product approvals.
  • Partnerships with Kite enhance Arcellx's research and development capabilities.

What critics are saying

  • Intensifying competition from companies like Bristol-Myers Squibb and Johnson & Johnson.
  • High development costs may limit accessibility of Arcellx's therapies.
  • Reliance on partnerships exposes Arcellx to partner performance risks.

What makes Arcellx unique

  • Arcellx's CART-ddBCMA has FDA Fast Track and Orphan Drug designations.
  • ARC-SparX offers dosable and controllable CAR-T therapy options.
  • Anito-cel uses a novel D-Domain BCMA binder for enhanced cell killing.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Unlimited Paid Time Off

Flexible Work Hours

401(k) Company Match

Fully-Paid Parental Leave

Tuition Reimbursement

Relocation Assistance

Growth & Insights and Company News

Headcount

6 month growth

-2%

1 year growth

0%

2 year growth

2%
Business Wire
Mar 20th, 2025
Arcellx Appoints Andrew Galligan and Kristin Myers to Its Board of Directors

Arcellx appoints Andrew Galligan and Kristin Myers to its Board of Directors.

BioSpace
Feb 28th, 2025
Arcellx To Participate At The Td Cowen 45Th Annual Health Care Conference

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced that management will participate in a fireside chat at the TD Cowen 45th Annual Health Care Conference on Wednesday, March 5, at 1:10 p.m. ET.A live webcast of this discussion will be accessible from Arcellx’s website at www.arcellx.com in the Investors section. A replay of the webcast will be archived and available for 30 days following the event.About Arcellx, Inc.Arcellx, Inc. is a clinical-stage biotechnology company reimagining cell therapy by engineering innovative immunotherapies for patients with cancer and other incurable diseases. Arcellx believes that cell therapies are one of the forward pillars of medicine and Arcellx’s mission is to advance humanity by developing cell therapies that are safer, more effective, and more broadly accessible

Business Wire
May 9th, 2024
Arcellx And Kite Continue Momentum With Advances In Anito-Cel Multiple Myeloma Program

REDWOOD CITY, Calif. SANTA MONICA, Calif.--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX) and Kite, a Gilead Company (NASDAQ: GILD), today announced several key operational updates on their partnered anitocabtagene autoleucel (anito-cel) multiple myeloma program. Anito-cel is the first BCMA CAR T to be investigated in multiple myeloma that utilizes Arcellx’s novel and compact D-Domain binder. The companies shared the design of a global, Phase 3 randomized controlled clinical trial, iMMagine-3, which Kite expects to start in the second half of this year. The trial will compare the efficacy and safety of anito-cel randomized against the standard of care (SOC) in patients with relapsed and/or refractory multiple myeloma (rrMM) who have received one to three prior lines of therapy, including an immunomodulatory drug (lMiD) and an anti-CD38 monoclonal antibody

Business Wire
May 9th, 2024
Kite And Arcellx Continue Momentum With Advances In Anito-Cel Multiple Myeloma Program

REDWOOD CITY, Calif. SANTA MONICA, Calif.--(BUSINESS WIRE)--Kite, a Gilead Company (NASDAQ: GILD), and Arcellx, Inc. (NASDAQ: ACLX) today announced several key operational updates on their partnered anitocabtagene autoleucel (anito-cel) multiple myeloma program. Anito-cel is the first BCMA CAR T to be investigated in multiple myeloma that utilizes Arcellx’s novel and compact D-Domain binder. The companies shared the design of a global, Phase 3 randomized controlled clinical trial, iMMagine-3, which Kite expects to start in the second half of this year. The trial will compare the efficacy and safety of anito-cel randomized against the standard of care (SOC) in patients with relapsed and/or refractory multiple myeloma (rrMM) who have received one to three prior lines of therapy, including an immunomodulatory drug (lMiD) and an anti-CD38 monoclonal antibody

Yahoo Finance
Mar 2nd, 2024
Earnings Update: Arcellx, Inc. (NASDAQ:ACLX) Just Reported And Analysts Are Boosting Their Estimates

Arcellx, Inc. (NASDAQ:ACLX) just released its full-year report and things are looking bullish.